Lynch syndrome-associated endometrial cancer patient with a rare novel germline likely pathogenic variant of MSH2 gene: A case report.

Endometrial cancer Germline Likely Pathogenic Variant Lynch syndrome MSH2

Journal

Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 27 02 2023
revised: 24 04 2023
accepted: 04 06 2023
medline: 12 7 2023
pubmed: 12 7 2023
entrez: 12 7 2023
Statut: epublish

Résumé

The Lynch syndrome (LS) is an autosomal dominant condition usually characterized by germline pathogenic variants in DNA mismatch repair (MMR) genes. Despite the guidelines now available, determining the pathogenicity of rare variants remains challenging, as the clinical significance of a genetic variant could be uncertain, but it may represent a disease-associated variation in the aforementioned genes. In this case report we will describe the case of a 47 years-old female affected by endometrial cancer (EC) with an extremely rare germline heterozygous variant in the MSH2 gene (c.562G > T p. (Glu188Ter), exon 3) that is likely pathogenic, and a family history consistent with LS.

Identifiants

pubmed: 37434947
doi: 10.1016/j.gore.2023.101220
pii: S2352-5789(23)00089-9
pmc: PMC10331303
doi:

Types de publication

Case Reports

Langues

eng

Pagination

101220

Informations de copyright

© 2023 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Dis Colon Rectum. 1991 May;34(5):424-5
pubmed: 2022152
Hum Mutat. 2008 Nov;29(11):1282-91
pubmed: 18951446
Gastroenterology. 2014 Mar;146(3):643-646.e8
pubmed: 24333619
Br J Surg. 2021 May 27;108(5):484-498
pubmed: 34043773
PLoS Genet. 2017 Apr 19;13(4):e1006739
pubmed: 28422960
J Clin Oncol. 2016 Sep 1;34(25):3062-8
pubmed: 27325856
Oncol Lett. 2019 Mar;17(3):3048-3054
pubmed: 30867733
QJM. 2016 Mar;109(3):151-8
pubmed: 26224055

Auteurs

L Zumstein (L)

Department of Oncology, University of Turin, Turin, Italy.

V Tuninetti (V)

Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital.

M Vaira (M)

Department of Surgical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.

D Siatis (D)

Department of Surgical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.

F Palermo (F)

Department of Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.

M Petracchini (M)

Department of Radiology, Umberto I Mauriziano Hospital, Turin, Italy.

G Scotto (G)

Department of Oncology, University of Turin, Turin, Italy.

M Turinetto (M)

Department of Oncology, University of Turin, Turin, Italy.

R Piva (R)

Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy.
Città Della Salute e della Scienza Hospital, 10126 Turin, Italy.

B Pasini (B)

Medical Genetics Unit at the AOU Città della Salute e della Scienza di Torino, Italy.
Department of Medical Sciences, University of Turin, Turin, Italy.

G Valabrega (G)

Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital.

Classifications MeSH